Table 2.
Comparison of baseline characteristics, MACE, adherence to medications, and lifestyle measures between both groups.
| Group A (n = 100) | Group B(n = 100) | p-value | |
|---|---|---|---|
| Baseline characteristics | |||
| Age in years (mean ± SD) | 56.2 ± 9.3 | 55.8 ± 11.2 | 0.8 |
| Male gender, % | 73 | 70 | 0.64 |
| HTN, % | 35 | 37 | 0.77 |
| DM, % | 36 | 35 | 0.88 |
| Smoking, % | 72 | 67 | 0.44 |
| IHD, % | 24 | 26 | 0.74 |
| Socioeconomic class | |||
| Very low, % | 26 | 24 | 0.92 |
| Low, % | 39 | 41 | |
| Middle, % | 34 | 33 | |
| High, % | 1 | 2 | |
| MACE | |||
| Overall MACE, % | 11 | 14 | 0.52 |
| Cardiovascular mortality, % | 1 | 2 | 0.56 |
| CVS, % | 1 | 1 | 1 |
| MI, % | 4 | 6 | 0.5 |
| TVR, % | 3 | 6 | 0.3 |
| HF hospitalization, % | 5 | 9 | 0.27 |
| Medication, smoking cessation and rehabilitation adherence | |||
| Aspirin, n (%) | 96 (96.9%) | 93 (94.9%) | 0.64 |
| P2Y12 inhibitor, n (%) | 96 (96.9%) | 93 (93%) | 0.64 |
| Statin, n (%) | 86 (86.8%) | 70 (71.4%) | 0.02* |
| BB, n (%) | 86 (86.8%) | 80 (81.6%) | 0.51 |
| ACE/ARB, n (%) | 62 (83.7%) | 42 (60%) | 0.006* |
| Rehabilitation, n (%) | 62 (62.6) | 29 (29.6) | ≤ 0.001* |
| Smoking cessation, n (%) | 54 (75%) | 26 (38.8%) | ≤ 0.001* |
HTN, hypertension; DM, diabetes mellitus; IHD, ischemic heart disease; CVS, cerebrovascular stroke; TVR, target vessel revascularization; HF, heart failure; MACE, major adverse cardiac events; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blockers; BB, B-blockers.
*
p-value is significant if < 0.05.